Modiodal (Modafinil)

Modafinil, the active ingredient in Modiodal, is a eugeroic presented as an oral tablet for oral use. It treats excessive daytime sleepiness in narcolepsy, obstructive sleep apnea, and shift work disorder.

GNH USA supplies Modiodal as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Modafinil is a central nervous system stimulant indicated for disorders of excessive daytime sleepiness.

- Narcolepsy: reduces daytime sleepiness and improves wakefulness. - Obstructive sleep apnea: helps mitigate residual sleepiness in patients using CPAP therapy. - Shift work disorder: promotes alertness during scheduled work hours.

Modiodal may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Insomnia: difficulty initiating or maintaining sleep. - Anxiety: feelings of nervousness or tension. - Dry mouth: reduced salivation. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Severe rash or Stevens‑Johnson syndrome: requires immediate medical attention. - Psychiatric symptoms: hallucinations, mania, or depression. - Cardiovascular events: hypertension, palpitations, or arrhythmia. - Allergic reactions: swelling, bronchospasm, or anaphylaxis. - Liver injury: elevated transaminases or hepatitis.

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients regularly.

- Cardiovascular assessment: screen for hypertension or arrhythmias. - Psychiatric history: monitor for anxiety, depression, or psychosis. - Hypersensitivity: avoid in patients with known allergy to modafinil. - Hepatic impairment: consider dose adjustment in severe liver disease. - Pregnancy and breastfeeding: safety not established; weigh benefits against potential risks. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Modiodal can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase modafinil plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may reduce hormonal efficacy. - Antidepressants (SSRIs, SNRIs): potential increase in side‑effect burden.